Your search results

Shortly after Crossject’s successful IPO on the French NYSE Euronext Paris Exchange (Paris Bourse), Patrick Alexandre spoke about Crossject, its technology and strategy for the future as a publically traded company.

Alan Smith outlines the stages of Type 2 diabetes treatment, progressing to extenatide and insulin injections, and makes the case, using clinical data, for the transdermal route as a viable alternative to injections.

Bruce K Redding Jnr gives an overview of the different types of transdermal patch design, as well as the various methods of getting through the skin.

Kevin Pang discusses the potential of transdermal delivery, how it has thus far failed to live up to it and how a combination of formulation and electronic advancements mean it could soon be realised.

Bruce K Redding Jr tells the story of the design and development of the U-Strip™ Insulin Transdermal Delivery System.

Paul Vescovo and Laurent-Dominique Piveteau discuss the design of the Debioject™ microneedle device and inserter, and its applications, particularly in intradermal delivery of vaccines.

ZENEO^® is a unique, automatic needle-free jet injector for SC, IM and ID routes, developed by Crossject. With ZENEO®, injection is fast, easy and secured.

Brian McMillan provides some insights into his personal experiences in the development of ophthalmic products and the significant role of innovative delivery systems in improving efficacy and reducing side-effects.

Daniel Bernards, Robert Bhisitkul and Tejal Desai discuss the development of a nanoporous membrane-based implant which can significantly improve drug delivery to the back of the eye.

Shikha Barman provides an overview of the current state of play in the ocular drug delivery market.